Hypereosinophilic Syndrome
Conditions
Brief summary
The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative and more accessible compared to those that we have already thanks to a proteomic approach. This will help the investigators to diagnose the this disease.
Interventions
BIOLOGICALbiologie sample
comparison of biomarkers between HES, HE biomarkers data and control arms
Sponsors
University Hospital, Lille
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* dated and signed informed consent * virale serology negative or negative result less than 6 months * virale serology negative for HBV or vaccinated patient * insured * virale serology negative or negative result less than 6 months * negative pregnancy test or female menopause for at least 1 year
Exclusion criteria
* subject enable adult, under guardianship or under protective measures of justice * Refusal or inability to give informed consent * The hypereosinophilic syndrome explained origin other than than atopy, bullous pemphigoid, the Churg-Strauss syndrome and DRESS
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim is to characterize, through an approach immunoprotéomique, new HES biomarkers more informative and easier access than those currently available to us. These biomarkers will help to the diagnosis of HES, compared with other causes of eosinophilia. | one month after patient inclusion |
Countries
France
Outcome results
None listed